Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 15/20 | 0.41 |
| ▸ | KIT | P10721 | 6/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776080 | 0.85 | FGFR4 (0.46) | FGFR4RPS6KA3RPS6KA2 | |
| SCHEMBL16776073 | 0.85 | FGFR4 (0.44) | FGFR4WNT1GSK3BDYRK1ARPS6KA3 | |
| SCHEMBL16776095 | 0.84 | FGFR4 (0.43) | FGFR4DYRK1ARPS6KA3RPS6KA2 | |
| SCHEMBL16776087 | 0.84 | EGFR (0.43) | FGFR4KDRRPS6KA3RPS6KA2 | |
| SCHEMBL16776131 | 0.84 | MCL1 (0.45) | RPS6KA3 | |
| SCHEMBL16776013 | 0.84 | FGFR4 (0.44) | FGFR4RPS6KA3RPS6KA2 | |
| SCHEMBL16776175 | 0.83 | FGFR4 (0.46) | FGFR4WNT1GSK3BDYRK1ARPS6KA3 | |
| SCHEMBL16776075 | 0.83 | FGFR4 (0.46) | FGFR4RPS6KA3RPS6KA2 | |
| SCHEMBL16776089 | 0.83 | FGFR4 (0.46) | FGFR4RPS6KA3RPS6KA2 | |
| SCHEMBL16776064 | 0.83 | ATR (0.47) | FGFR4RPS6KA3RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FGFR4 1754/4885CSF1R 2306/4885KIT 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.